Literature DB >> 21688998

Electroporation-aided DNA immunization generates polyclonal antibodies against the native conformation of human endothelin B receptor.

Bertrand Allard1, Fabienne Priam, Frédérique Deshayes, Frédéric Ducancel, Didier Boquet, Anne Wijkhuisen, Jean-Yves Couraud.   

Abstract

Endothelin B receptor (ET(B)R) is a G protein-coupled receptor (GPCR) specific for endothelin peptides (including endothelin-1, ET1), which mediates a variety of key physiological functions in normal tissues, such as modulation of vasomotor tone, tissue differentiation, or cell proliferation. Moreover, ET(B)R, overexpressed in various cancer cells including melanoma, has been implicated in the growth and progression of tumors, as well as in controlling T cell homing to tumors. To gather information on receptor structure and function, antibodies are generally considered choice molecular probes, but generation of such reagents against the native conformation of GPCRs is a real technical challenge. Here, we show that electroporation-aided genetic immunization, coupled to cardiotoxin pretreatment, is a simple and very efficient method to raise large amounts of polyclonal antibodies highly specific for native human ET(B)R (hET(B)R), as assessed by both flow cytometry analysis of different stably transfected cell lines and a new and rapid cell-based enzyme-linked immunosorbent assay that we also describe. The antibodies recognized two major epitopes on hET(B)R, mapped within the N-terminal extracellular domain. They were used to reveal hET(B)R on membranes of three different human melanoma cell lines, by flow cytometry and confocal microscopy, a method that we show is more relevant than mRNA polymerase chain reaction in assessing receptor expression. In addition, ET-1 partially competed with antibodies for receptor binding. The strategy described here, thus, efficiently generated new immunological tools to further analyze the role of ET(B)R under both normal and pathological conditions, including cancers. Above all, it can now be used to raise monoclonal antibodies against hET(B)R and, more generally, against GPCRs that constitute, by far, the largest reservoir of potential pharmacological targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688998     DOI: 10.1089/dna.2011.1239

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  5 in total

1.  Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.

Authors:  Aurélie Borrull; Bertrand Allard; Anne Wijkhuisen; Amaury Herbet; Patricia Lamourette; Wided Birouk; Denis Leiber; Zahra Tanfin; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud; Philippe Robin
Journal:  MAbs       Date:  2016-07-08       Impact factor: 5.857

Review 2.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

3.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

4.  From ugly duckling to swan: unexpected identification from cell-SELEX of an anti-Annexin A2 aptamer targeting tumors.

Authors:  Agnes Cibiel; Nam Nguyen Quang; Karine Gombert; Benoit Thézé; Anikitos Garofalakis; Frédéric Ducongé
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

5.  Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.

Authors:  Julie A Douthwaite; Sudharsan Sridharan; Catherine Huntington; Jayne Hammersley; Rose Marwood; Jonna K Hakulinen; Margareta Ek; Tove Sjögren; David Rider; Cyril Privezentzev; Jonathan C Seaman; Peter Cariuk; Vikki Knights; Joyce Young; Trevor Wilkinson; Matthew Sleeman; Donna K Finch; David C Lowe; Tristan J Vaughan
Journal:  MAbs       Date:  2015       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.